DK3527263T3 - Bipyrazolderivater som jak-inhibitorer - Google Patents

Bipyrazolderivater som jak-inhibitorer Download PDF

Info

Publication number: DK3527263T3
Authority: DK; Denmark
Prior art keywords: jak inhibitors; bipyrazole derivatives; bipyrazole; derivatives; jak
Prior art date: 2013-05-17

Application number

DK18215671.1T

Other languages

English (en)

Inventor

Yun-Long Li

Jincong Zhuo

Ding-Quan Qian

Song Mei

Ganfeng Cao

Yongchun Pan

Qun Li

Zhongjiang Jia

Original Assignee

Incyte Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-17

Filing date

2014-05-16

Publication date

2021-01-25

2014-05-16 Application filed by Incyte Corp filed Critical Incyte Corp

2021-01-25 Application granted granted Critical

2021-01-25 Publication of DK3527263T3 publication Critical patent/DK3527263T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Biotechnology (AREA)
Dermatology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK18215671.1T 2013-05-17 2014-05-16 Bipyrazolderivater som jak-inhibitorer DK3527263T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361824683P	2013-05-17	2013-05-17
EP17158350.3A EP3231801B1 (en)	2013-05-17	2014-05-16	Bipyrazole salt as jak inhibitor

Publications (1)

Publication Number	Publication Date
DK3527263T3 true DK3527263T3 (da)	2021-01-25

Family

ID=50983151

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK17158350.3T DK3231801T3 (da)	2013-05-17	2014-05-16	Bipyrazolsalt som jak-inhibitor
DK20201593.9T DK3786162T3 (da)	2013-05-17	2014-05-16	Bipyrazolderivater som jak-inhibitorer
DK18215671.1T DK3527263T3 (da)	2013-05-17	2014-05-16	Bipyrazolderivater som jak-inhibitorer
DK23185889.5T DK4275756T3 (da)	2013-05-17	2014-05-16	Bipyrazol-derivater som jak-hæmmere

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK17158350.3T DK3231801T3 (da)	2013-05-17	2014-05-16	Bipyrazolsalt som jak-inhibitor
DK20201593.9T DK3786162T3 (da)	2013-05-17	2014-05-16	Bipyrazolderivater som jak-inhibitorer

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK23185889.5T DK4275756T3 (da)	2013-05-17	2014-05-16	Bipyrazol-derivater som jak-hæmmere

Country Status (36)

Country	Link
US (8)	US9382231B2 (da)
EP (6)	EP3527263B1 (da)
JP (5)	JP6415543B2 (da)
KR (4)	KR102341908B1 (da)
CN (2)	CN107698569B (da)
AR (2)	AR096330A1 (da)
AU (5)	AU2014265279B2 (da)
BR (1)	BR112015028501B8 (da)
CA (1)	CA2911536C (da)
CL (1)	CL2015003355A1 (da)
CR (2)	CR20190156A (da)
CY (3)	CY1119105T1 (da)
DK (4)	DK3231801T3 (da)
EA (2)	EA036448B1 (da)
ES (4)	ES2720073T3 (da)
FI (2)	FI3786162T3 (da)
HK (1)	HK1245769B (da)
HR (4)	HRP20231048T1 (da)
HU (4)	HUE053122T2 (da)
IL (4)	IL242453B (da)
LT (5)	LT3786162T (da)
ME (2)	ME03355B (da)
MX (2)	MX385187B (da)
MY (1)	MY174788A (da)
PE (2)	PE20160126A1 (da)
PH (2)	PH12015502563B1 (da)
PL (4)	PL3231801T3 (da)
PT (5)	PT3527263T (da)
RS (4)	RS56012B1 (da)
SG (2)	SG11201509180WA (da)
SI (4)	SI3786162T1 (da)
SM (5)	SMT202500397T1 (da)
TR (1)	TR201905814T4 (da)
TW (4)	TWI840646B (da)
UA (1)	UA117830C2 (da)
WO (1)	WO2014186706A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2426129T1 (sl)	2005-12-13	2017-02-28	Incyte Holdings Corporation	Heteroarilno substituirani pirolo(2,3-b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janusove kinaze
MX342814B (es)	2007-06-13	2016-10-13	Incyte Holdings Corp	Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
HUE046493T2 (hu)	2009-05-22	2020-03-30	Incyte Holdings Corp	3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként
CN102458581B (zh)	2009-05-22	2016-03-30	因塞特控股公司	作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2，3-d]嘧啶和吡咯-3-基-吡咯并[2，3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
CN104945420A (zh)	2009-06-29	2015-09-30	因塞特公司	作为pi3k抑制剂的嘧啶酮类
WO2011028685A1 (en)	2009-09-01	2011-03-10	Incyte Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
RS57219B1 (sr)	2010-03-10	2018-07-31	Incyte Holdings Corp	Piperidin-4-il azetidin derivati kao inhibitori jak1
EP3087972A1 (en)	2010-05-21	2016-11-02	Incyte Holdings Corporation	Topical formulation for a jak inhibitor
SG190839A1 (en)	2010-11-19	2013-07-31	Incyte Corp	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CA2822070C (en)	2010-12-20	2019-09-17	Incyte Corporation	N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
PH12013502612A1 (en)	2011-06-20	2014-04-28	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
ES2873001T3 (es)	2011-09-02	2021-11-03	Incyte Holdings Corp	Heterociclaminas como inhibidores de PI3K
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2013173720A1 (en)	2012-05-18	2013-11-21	Incyte Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TWI646099B (zh)	2012-11-01	2019-01-01	英塞特控股公司	作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
TW202228704A (zh)	2012-11-15	2022-08-01	美商英塞特控股公司	盧梭利替尼之緩釋性劑型
BR122021015061B1 (pt)	2013-03-06	2022-10-18	Incyte Holdings Corporation	Processos e intermediários para preparar um inibidor de jak
CN107698569B (zh) *	2013-05-17	2020-11-27	因赛特公司	作为jak抑制剂的联吡唑衍生物
DK3030227T3 (da)	2013-08-07	2020-04-20	Incyte Corp	Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
SMT201800551T1 (it) *	2014-02-28	2019-01-11	Incyte Corp	Inibitori di jak1 per il trattamento di sindromi mielodisplastiche
EP3129021B1 (en)	2014-04-08	2020-09-23	Incyte Corporation	Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
PE20170300A1 (es)	2014-04-30	2017-04-19	Incyte Corp	Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en)	2014-06-11	2015-12-17	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016172712A2 (en)	2015-04-23	2016-10-27	Sydnexis, Inc.	Ophthalmic composition
US9421199B2 (en)	2014-06-24	2016-08-23	Sydnexis, Inc.	Ophthalmic composition
US11382909B2 (en)	2014-09-05	2022-07-12	Sydnexis, Inc.	Ophthalmic composition
WO2016130501A1 (en)	2015-02-09	2016-08-18	Incyte Corporation	Aza-heteroaryl compounds as pi3k-gamma inhibitors
JP6816005B2 (ja)	2015-02-27	2021-01-20	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｐｉ３ｋ阻害剤の塩及びその調製のためのプロセス
WO2016183060A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
CN107847432A (zh)	2015-05-29	2018-03-27	西德奈克西斯公司	D2o稳定化的药物制剂
ES2915550T3 (es)	2015-11-06	2022-06-23	Incyte Corp	Compuestos heterocíclicos como inhibidores de PI3K-gamma
WO2017120194A1 (en)	2016-01-05	2017-07-13	Incyte Corporation	Pyridine and pyridimine compounds as pi3k-gamma inhibitors
WO2017223414A1 (en)	2016-06-24	2017-12-28	Incyte Corporation	HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
CN107759623B (zh) *	2016-08-23	2020-08-14	苏州旺山旺水生物医药有限公司	Jak抑制剂的中间体及其制备方法
WO2018046409A1 (en) *	2016-09-06	2018-03-15	F. Hoffmann-La Roche Ag	8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
SMT202100656T1 (it)	2017-10-18	2022-01-10	Incyte Corp	Derivati di imidazolo condensati sostituiti con gruppi ossidrile terziari come inibitori di pi3k-gamma
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3089832A1 (en)	2018-01-30	2019-08-08	Incyte Corporation	Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
KR20240157777A (ko) *	2018-02-16	2024-11-01	인사이트 코포레이션	사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
IL318069A (en) *	2018-03-30	2025-02-01	Incyte Corp	Using JAK inhibitors to treat hidradenitis suppurativa
WO2019191679A1 (en)	2018-03-30	2019-10-03	Incyte Corporation	Biomarkers for inflammatory skin disease
JP7378420B2 (ja)	2018-04-13	2023-11-13	インサイト・コーポレイション	移植片対宿主病のバイオマーカー
CN108484468A (zh) *	2018-05-11	2018-09-04	南京大学	芳基氮杂环丁烷类化合物的制备方法
MA52761A (fr)	2018-06-01	2021-04-14	Incyte Corp	Schéma posologique destiné au traitement de troubles liés à la pi3k
CR20250050A (es)	2018-09-05	2025-03-19	Incyte Corp	Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
EA202191170A1 (ru)	2018-10-31	2021-07-27	Инсайт Корпорейшн	Комбинированная терапия для лечения гематологических заболеваний
PH12021551455A1 (en)	2018-12-19	2022-04-18	Incyte Corp	Jak1 pathway inhibitors for the treatment of gastrointestinal disease
PH12021552130A1 (en)	2019-03-05	2022-08-31	Incyte Corp	Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11624751B2 (en)	2019-03-19	2023-04-11	Incyte Corporation	Biomarkers for vitiligo
BR112021018168B1 (pt)	2019-03-21	2023-11-28	Onxeo	Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN114761013A (zh)	2019-09-27	2022-07-15	迪斯克医药公司	治疗骨髓纤维化和相关病症的方法
US12360120B2 (en)	2019-10-10	2025-07-15	Incyte Corporation	Biomarkers for graft-versus-host disease
JP2022551649A (ja)	2019-10-10	2022-12-12	インサイト・コーポレイション	移植片対宿主病のバイオマーカー
WO2021076124A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11992490B2 (en)	2019-10-16	2024-05-28	Incyte Corporation	Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
JP2023528223A (ja)	2020-05-13	2023-07-04	ディスク・メディシン・インコーポレイテッド	骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
BR112022024632A2 (pt) *	2020-06-02	2023-02-28	Incyte Corp	Processos para preparar um inibidor de jak1
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022040180A1 (en)	2020-08-18	2022-02-24	Incyte Corporation	Process and intermediates for preparing a jak inhibitor
PE20231308A1 (es)	2020-08-18	2023-08-24	Incyte Corp	Proceso e intermedios para preparar un inhibidor de jak1
CN112159394B (zh) *	2020-10-09	2021-10-22	嘉兴特科罗生物科技有限公司	一种作为jak激酶抑制剂的小分子化合物及其用途
SMT202500205T1 (it)	2020-12-04	2025-07-22	Incyte Corp	Inibitore di jak con un analogo di vitamina d per il trattamento di malattie della pelle
MX2023006542A (es)	2020-12-08	2023-08-25	Incyte Corp	Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
CN112933095A (zh) *	2020-12-29	2021-06-11	上海岸阔医药科技有限公司	预防或治疗egfr功能异常相关的副作用的方法
MX2023008141A (es)	2021-01-11	2023-10-20	Incyte Corp	Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock).
DK4333840T3 (da)	2021-05-03	2025-11-24	Incyte Corp	Jak1-vejinhibitorer til behandling af prurigo nodularis
WO2023288197A1 (en)	2021-07-12	2023-01-19	Incyte Corporation	Process and intermediates for preparing baricitinib
KR20250044437A (ko)	2022-08-05	2025-03-31	인사이트 코포레이션	Jak 억제제를 사용한 두드러기의 치료
WO2024192350A1 (en)	2023-03-16	2024-09-19	Incyte Corporation	Jak1 pathway inhibitors for the treatment of asthma
CN117186078A (zh) *	2023-11-06	2023-12-08	药康众拓(北京)医药科技有限公司	氘代氮杂环丁烷类jak抑制剂药物及用途
US20250325664A1 (en)	2024-04-22	2025-10-23	Incyte Corporation	Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60106847U (ja)	1983-12-27	1985-07-20	富士重工業株式会社	室外後写鏡
JP2650681B2 (ja)	1987-07-10	1997-09-03	株式会社ブリヂストン	空気ばね
JPH0515775Y2 (da)	1987-07-13	1993-04-26
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
EP1107964B8 (en)	1998-08-11	2010-04-07	Novartis AG	Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en)	1999-08-19	2000-10-17	Isis Pharmaceuticals Inc.	Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
EP1294358B1 (en)	2000-06-28	2004-08-18	Smithkline Beecham Plc	Wet milling process
CA2466243A1 (en)	2001-09-19	2003-03-27	Aventis Pharma S.A.	Indolizines as kinase protein inhibitors
TWI302836B (en)	2001-10-30	2008-11-11	Novartis Ag	Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
PE20040522A1 (es)	2002-05-29	2004-09-28	Novartis Ag	Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
AR042052A1 (es)	2002-11-15	2005-06-08	Vertex Pharma	Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
PE20050952A1 (es)	2003-09-24	2005-12-19	Novartis Ag	Derivados de isoquinolina como inhibidores de b-raf
JP2008520612A (ja)	2004-11-24	2008-06-19	ノバルティスアクチエンゲゼルシャフト	ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
SI2426129T1 (sl)	2005-12-13	2017-02-28	Incyte Holdings Corporation	Heteroarilno substituirani pirolo(2,3-b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janusove kinaze
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX342814B (es)	2007-06-13	2016-10-13	Incyte Holdings Corp	Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
AU2008321046B2 (en) *	2007-11-16	2013-10-24	Incyte Holdings Corporation	4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
SI2288610T1 (sl) *	2008-03-11	2016-11-30	Incyte Holdings Corporation	Derivati azetidina in ciklobutana kot inhibitorji jak
CL2009001884A1 (es)	2008-10-02	2010-05-14	Incyte Holdings Corp	Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CN102458581B (zh)	2009-05-22	2016-03-30	因塞特控股公司	作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2，3-d]嘧啶和吡咯-3-基-吡咯并[2，3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
HUE046493T2 (hu)	2009-05-22	2020-03-30	Incyte Holdings Corp	3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként
WO2011028685A1 (en)	2009-09-01	2011-03-10	Incyte Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP5946768B2 (ja)	2009-10-09	2016-07-06	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	３−（４−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１Ｈ−ピラゾール−１−イル）−３−シクロペンチルプロパンニトリルのヒドロキシル、ケト及びグルクロニド誘導体
MX2012009541A (es)	2010-02-18	2012-10-01	Incyte Corp	Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa.
RS57219B1 (sr)	2010-03-10	2018-07-31	Incyte Holdings Corp	Piperidin-4-il azetidin derivati kao inhibitori jak1
WO2011130146A1 (en) *	2010-04-14	2011-10-20	Array Biopharma Inc.	5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP3087972A1 (en)	2010-05-21	2016-11-02	Incyte Holdings Corporation	Topical formulation for a jak inhibitor
ES2536415T3 (es)	2010-11-19	2015-05-25	Incyte Corporation	Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
SG190839A1 (en)	2010-11-19	2013-07-31	Incyte Corp	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2545110T3 (es)	2010-12-10	2015-09-08	Rottapharm Biotech S.R.L.	Derivados de piridinamida como antagonistas del receptor EP4
WO2012116248A1 (en)	2011-02-24	2012-08-30	Massachusetts Institute Of Technology	ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
PH12013502612A1 (en)	2011-06-20	2014-04-28	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) *	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
ES2640911T3 (es)	2011-09-22	2017-11-07	Merck Sharp & Dohme Corp.	Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
WO2013173720A1 (en) *	2012-05-18	2013-11-21	Incyte Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TWI646099B (zh)	2012-11-01	2019-01-01	英塞特控股公司	作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
TW202228704A (zh)	2012-11-15	2022-08-01	美商英塞特控股公司	盧梭利替尼之緩釋性劑型
BR122021015061B1 (pt)	2013-03-06	2022-10-18	Incyte Holdings Corporation	Processos e intermediários para preparar um inibidor de jak
JO3603B1 (ar)	2013-05-17	2020-07-05	Janssen Sciences Ireland Uc	مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US9371282B2 (en)	2013-05-17	2016-06-21	Centrexion Therapeutics Corporation	Somatostatin receptor subtype 4 (SSTR4) agonists
BR112015028873A2 (pt)	2013-05-17	2017-07-25	Hoffmann La Roche	heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
CN107698569B (zh)	2013-05-17	2020-11-27	因赛特公司	作为jak抑制剂的联吡唑衍生物
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
DK3030227T3 (da)	2013-08-07	2020-04-20	Incyte Corp	Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
SMT201800551T1 (it)	2014-02-28	2019-01-11	Incyte Corp	Inibitori di jak1 per il trattamento di sindromi mielodisplastiche
PE20170300A1 (es)	2014-04-30	2017-04-19	Incyte Corp	Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
HUE047225T2 (hu)	2014-12-16	2020-04-28	Novartis Ag	LpxC inhibitor izoxazol hidroxámsav-vegyületek
KR20240157777A (ko)	2018-02-16	2024-11-01	인사이트 코포레이션	사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
BR112022024632A2 (pt)	2020-06-02	2023-02-28	Incyte Corp	Processos para preparar um inibidor de jak1
SMT202500205T1 (it)	2020-12-04	2025-07-22	Incyte Corp	Inibitore di jak con un analogo di vitamina d per il trattamento di malattie della pelle
MX2023006542A (es)	2020-12-08	2023-08-25	Incyte Corp	Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.

2014
- 2014-05-16 CN CN201711000293.3A patent/CN107698569B/zh active Active
- 2014-05-16 KR KR1020157035750A patent/KR102341908B1/ko active Active
- 2014-05-16 HU HUE18215671A patent/HUE053122T2/hu unknown
- 2014-05-16 CA CA2911536A patent/CA2911536C/en active Active
- 2014-05-16 TW TW110101630A patent/TWI840646B/zh active
- 2014-05-16 PL PL17158350T patent/PL3231801T3/pl unknown
- 2014-05-16 LT LTEP20201593.9T patent/LT3786162T/lt unknown
- 2014-05-16 DK DK17158350.3T patent/DK3231801T3/da active
- 2014-05-16 RS RS20170526A patent/RS56012B1/sr unknown
- 2014-05-16 SM SM20250397T patent/SMT202500397T1/it unknown
- 2014-05-16 PT PT182156711T patent/PT3527263T/pt unknown
- 2014-05-16 MX MX2020004506A patent/MX385187B/es unknown
- 2014-05-16 KR KR1020227030853A patent/KR102663357B1/ko active Active
- 2014-05-16 AR ARP140101971A patent/AR096330A1/es active IP Right Grant
- 2014-05-16 LT LTEP17158350.3T patent/LT3231801T/lt unknown
- 2014-05-16 MY MYPI2015002767A patent/MY174788A/en unknown
- 2014-05-16 PL PL20201593.9T patent/PL3786162T3/pl unknown
- 2014-05-16 EP EP18215671.1A patent/EP3527263B1/en active Active
- 2014-05-16 HU HUE20201593A patent/HUE063817T2/hu unknown
- 2014-05-16 DK DK20201593.9T patent/DK3786162T3/da active
- 2014-05-16 AU AU2014265279A patent/AU2014265279B2/en active Active
- 2014-05-16 SM SM20190223T patent/SMT201900223T1/it unknown
- 2014-05-16 RS RS20210074A patent/RS61482B1/sr unknown
- 2014-05-16 LT LTEP23185889.5T patent/LT4275756T/lt unknown
- 2014-05-16 SI SI201432046T patent/SI3786162T1/sl unknown
- 2014-05-16 CR CR20190156A patent/CR20190156A/es unknown
- 2014-05-16 PE PE2015002406A patent/PE20160126A1/es unknown
- 2014-05-16 KR KR1020217030190A patent/KR102442747B1/ko active Active
- 2014-05-16 ME MEP-2019-79A patent/ME03355B/me unknown
- 2014-05-16 TR TR2019/05814T patent/TR201905814T4/tr unknown
- 2014-05-16 EP EP25180368.0A patent/EP4620528A3/en active Pending
- 2014-05-16 HR HRP20231048TT patent/HRP20231048T1/hr unknown
- 2014-05-16 PT PT147327050T patent/PT2997023T/pt unknown
- 2014-05-16 PT PT202015939T patent/PT3786162T/pt unknown
- 2014-05-16 RS RS20230782A patent/RS64591B1/sr unknown
- 2014-05-16 MX MX2015015738A patent/MX373238B/es active IP Right Grant
- 2014-05-16 HU HUE14732705A patent/HUE033587T2/hu unknown
- 2014-05-16 ES ES17158350T patent/ES2720073T3/es active Active
- 2014-05-16 DK DK18215671.1T patent/DK3527263T3/da active
- 2014-05-16 HR HRP20170795TT patent/HRP20170795T1/hr unknown
- 2014-05-16 EA EA201592199A patent/EA036448B1/ru unknown
- 2014-05-16 EP EP20201593.9A patent/EP3786162B1/en active Active
- 2014-05-16 BR BR112015028501A patent/BR112015028501B8/pt active IP Right Grant
- 2014-05-16 ES ES14732705.0T patent/ES2626793T3/es active Active
- 2014-05-16 SG SG11201509180WA patent/SG11201509180WA/en unknown
- 2014-05-16 PT PT231858895T patent/PT4275756T/pt unknown
- 2014-05-16 SI SI201431118T patent/SI3231801T1/sl unknown
- 2014-05-16 KR KR1020247014111A patent/KR102729910B1/ko active Active
- 2014-05-16 CN CN201480032106.8A patent/CN105452239B/zh active Active
- 2014-05-16 DK DK23185889.5T patent/DK4275756T3/da active
- 2014-05-16 FI FIEP20201593.9T patent/FI3786162T3/fi active
- 2014-05-16 US US14/279,929 patent/US9382231B2/en active Active
- 2014-05-16 EP EP14732705.0A patent/EP2997023B9/en active Active
- 2014-05-16 SM SM20230352T patent/SMT202300352T1/it unknown
- 2014-05-16 SI SI201430239A patent/SI2997023T1/sl unknown
- 2014-05-16 ME MEP-2017-116A patent/ME02763B/me unknown
- 2014-05-16 EA EA202090291A patent/EA039660B1/ru unknown
- 2014-05-16 SG SG10201709469SA patent/SG10201709469SA/en unknown
- 2014-05-16 PT PT17158350T patent/PT3231801T/pt unknown
- 2014-05-16 TW TW112149597A patent/TWI885650B/zh active
- 2014-05-16 RS RS20190315A patent/RS58743B1/sr unknown
- 2014-05-16 PL PL18215671T patent/PL3527263T3/pl unknown
- 2014-05-16 LT LTEP14732705.0T patent/LT2997023T/lt unknown
- 2014-05-16 WO PCT/US2014/038388 patent/WO2014186706A1/en not_active Ceased
- 2014-05-16 FI FIEP23185889.5T patent/FI4275756T3/fi active
- 2014-05-16 ES ES18215671T patent/ES2845210T3/es active Active
- 2014-05-16 SM SM20210040T patent/SMT202100040T1/it unknown
- 2014-05-16 LT LTEP18215671.1T patent/LT3527263T/lt unknown
- 2014-05-16 ES ES20201593T patent/ES2960731T3/es active Active
- 2014-05-16 TW TW103117400A patent/TWI664176B/zh active
- 2014-05-16 UA UAA201512465A patent/UA117830C2/uk unknown
- 2014-05-16 JP JP2016514126A patent/JP6415543B2/ja active Active
- 2014-05-16 SM SM20170258T patent/SMT201700258T1/it unknown
- 2014-05-16 HU HUE17158350A patent/HUE043573T2/hu unknown
- 2014-05-16 PE PE2020000001A patent/PE20200527A1/es unknown
- 2014-05-16 EP EP23185889.5A patent/EP4275756B1/en active Active
- 2014-05-16 SI SI201431754T patent/SI3527263T1/sl unknown
- 2014-05-16 PL PL14732705T patent/PL2997023T3/pl unknown
- 2014-05-16 TW TW108103947A patent/TWI719401B/zh active
- 2014-05-16 EP EP17158350.3A patent/EP3231801B1/en active Active
2015
- 2015-11-04 IL IL24245315A patent/IL242453B/en active IP Right Grant
- 2015-11-12 PH PH12015502563A patent/PH12015502563B1/en unknown
- 2015-11-13 CL CL2015003355A patent/CL2015003355A1/es unknown
- 2015-12-03 CR CR20150633A patent/CR20150633A/es unknown
2016
- 2016-06-20 US US15/187,296 patent/US9926301B2/en active Active
2017
- 2017-06-08 CY CY20171100610T patent/CY1119105T1/el unknown
2018
- 2018-02-15 US US15/897,598 patent/US10435392B2/en active Active
- 2018-04-18 HK HK18105021.2A patent/HK1245769B/en unknown
- 2018-08-31 AU AU2018223058A patent/AU2018223058B2/en active Active
- 2018-10-02 PH PH12018502125A patent/PH12018502125A1/en unknown
- 2018-10-02 JP JP2018187613A patent/JP6775560B2/ja active Active
2019
- 2019-01-22 IL IL264409A patent/IL264409B/en active IP Right Grant
- 2019-04-16 HR HRP20190713TT patent/HRP20190713T1/hr unknown
- 2019-05-10 CY CY20191100510T patent/CY1121763T1/el unknown
- 2019-08-29 US US16/555,620 patent/US11001571B2/en active Active
2020
- 2020-02-17 AR ARP200100433A patent/AR118120A2/es unknown
- 2020-03-19 AU AU2020202000A patent/AU2020202000B2/en active Active
- 2020-10-06 JP JP2020168950A patent/JP7126741B2/ja active Active
2021
- 2021-01-22 CY CY20211100050T patent/CY1123756T1/el unknown
- 2021-01-22 HR HRP20210119TT patent/HRP20210119T1/hr unknown
- 2021-04-13 US US17/229,397 patent/US11591318B2/en active Active
- 2021-04-26 IL IL282644A patent/IL282644B/en unknown
- 2021-04-29 AU AU2021202685A patent/AU2021202685B2/en active Active
- 2021-10-17 IL IL287313A patent/IL287313B/en unknown
2022
- 2022-08-10 JP JP2022128042A patent/JP2022163162A/ja active Pending
- 2022-10-31 AU AU2022263454A patent/AU2022263454B2/en active Active
2023
- 2023-01-24 US US18/101,014 patent/US11905275B2/en active Active
2024
- 2024-01-02 US US18/402,493 patent/US12247020B2/en active Active
- 2024-05-15 JP JP2024079435A patent/JP2024105557A/ja active Pending
2025
- 2025-02-05 US US19/045,868 patent/US20250206726A1/en active Pending

Also Published As

Publication number	Publication date
EP4275756A3 (en)	2024-02-07
MX373238B (es)	2020-05-08
MX2015015738A (es)	2016-03-16
TWI664176B (zh)	2019-07-01
EA036448B1 (ru)	2020-11-11
CN107698569B (zh)	2020-11-27
JP6415543B2 (ja)	2018-10-31
EP3786162B1 (en)	2023-08-09
NZ753638A (en)	2020-11-27
CR20190156A (es)	2019-05-16
ME02763B (me)	2018-01-20
PT3786162T (pt)	2023-10-20
JP2024105557A (ja)	2024-08-06
BR112015028501B1 (pt)	2022-11-01
CY1123756T1 (el)	2022-05-27
CN107698569A (zh)	2018-02-16
ES2720073T3 (es)	2019-07-17
SG11201509180WA (en)	2015-12-30
SMT201700258T1 (it)	2017-07-18
HRP20210119T1 (hr)	2021-03-05
JP2019011364A (ja)	2019-01-24
EA201592199A1 (ru)	2016-05-31
SG10201709469SA (en)	2017-12-28
EP2997023B9 (en)	2018-06-13
HK1245769B (en)	2020-02-07
AU2020202000B2 (en)	2021-03-11
IL282644B (en)	2021-10-31
NZ753637A (en)	2020-11-27
TW202432140A (zh)	2024-08-16
AU2018223058B2 (en)	2020-01-02
TWI840646B (zh)	2024-05-01
JP7126741B2 (ja)	2022-08-29
SI3527263T1 (sl)	2021-05-31
AU2018223058A1 (en)	2018-09-20
PL3786162T3 (pl)	2024-04-08
NZ713999A (en)	2020-11-27
US20140343030A1 (en)	2014-11-20
EP4620528A3 (en)	2025-11-26
CR20150633A (es)	2016-04-05
ES2960731T3 (es)	2024-03-06
EA039660B1 (ru)	2022-02-24
LT3527263T (lt)	2021-05-10
MX385187B (es)	2025-03-14
IL242453B (en)	2019-11-28
JP2022163162A (ja)	2022-10-25
AR118120A2 (es)	2021-09-22
HRP20170795T1 (hr)	2017-08-25
HUE033587T2 (hu)	2017-12-28
LT3231801T (lt)	2019-08-12
US20200010456A1 (en)	2020-01-09
KR20210120120A (ko)	2021-10-06
BR112015028501A2 (pt)	2017-07-25
MX2020004506A (es)	2021-08-09
EA202090291A3 (ru)	2020-06-30
DK4275756T3 (da)	2025-09-29
TW201512191A (zh)	2015-04-01
EP4620528A2 (en)	2025-09-24
ME03355B (me)	2019-10-20
IL287313B (en)	2022-03-01
HK1221466A1 (en)	2017-06-02
JP2016519147A (ja)	2016-06-30
RS56012B1 (sr)	2017-09-29
KR102341908B1 (ko)	2021-12-23
US9926301B2 (en)	2018-03-27
LT3786162T (lt)	2023-11-27
PL3231801T3 (pl)	2019-07-31
KR20160019905A (ko)	2016-02-22
PE20160126A1 (es)	2016-02-24
BR112015028501B8 (pt)	2023-01-24
AU2021202685A1 (en)	2021-05-27
DK3786162T3 (da)	2023-10-09
TW201940479A (zh)	2019-10-16
KR20220127371A (ko)	2022-09-19
PL2997023T3 (pl)	2017-08-31
PE20200527A1 (es)	2020-03-09
EP3786162A1 (en)	2021-03-03
PT4275756T (pt)	2025-10-31
ES2626793T3 (es)	2017-07-26
EP3527263B1 (en)	2020-10-28
RS58743B1 (sr)	2019-06-28
EP4275756A2 (en)	2023-11-15
PH12015502563A1 (en)	2016-02-22
CA2911536A1 (en)	2014-11-20
US11591318B2 (en)	2023-02-28
SI3231801T1 (sl)	2019-05-31
US11905275B2 (en)	2024-02-20
KR102442747B1 (ko)	2022-09-14
TWI885650B (zh)	2025-06-01
CN105452239B (zh)	2017-11-21
FI4275756T3 (fi)	2025-10-20
PT3231801T (pt)	2019-05-24
EP4275756B1 (en)	2025-09-03
SMT202500397T1 (it)	2025-11-10
KR102663357B1 (ko)	2024-05-14
US20180312492A1 (en)	2018-11-01
HRP20190713T1 (hr)	2019-06-14
LT4275756T (lt)	2025-11-10
US11001571B2 (en)	2021-05-11
FI3786162T3 (fi)	2023-10-02
HUE063817T2 (hu)	2024-01-28
AR096330A1 (es)	2015-12-23
SMT202300352T1 (it)	2024-01-10
CL2015003355A1 (es)	2016-05-27
US20210238168A1 (en)	2021-08-05
EP3231801A1 (en)	2017-10-18
AU2022263454A1 (en)	2022-12-08
JP6775560B2 (ja)	2020-10-28
RS61482B1 (sr)	2021-03-31
TR201905814T4 (tr)	2019-05-21
AU2022263454B2 (en)	2024-01-18
MY174788A (en)	2020-05-14
CY1119105T1 (el)	2018-02-14
ES2845210T3 (es)	2021-07-26
SI3786162T1 (sl)	2024-02-29
KR20240063187A (ko)	2024-05-10
HRP20231048T1 (hr)	2023-12-22
EP2997023B1 (en)	2017-03-22
HUE043573T2 (hu)	2019-08-28
PT3527263T (pt)	2021-02-01
US12247020B2 (en)	2025-03-11
PH12018502125A1 (en)	2019-03-25
HUE053122T2 (hu)	2021-06-28
UA117830C2 (uk)	2018-10-10
WO2014186706A1 (en)	2014-11-20
LT2997023T (lt)	2017-06-26
AU2014265279A1 (en)	2015-11-26
PL3527263T3 (pl)	2021-05-17
CN105452239A (zh)	2016-03-30
EA202090291A2 (ru)	2020-05-31
US20240150327A1 (en)	2024-05-09
KR102729910B1 (ko)	2024-11-15
AU2020202000A1 (en)	2020-04-09
DK3231801T3 (da)	2019-04-15
SI2997023T1 (sl)	2017-07-31
NZ753639A (en)	2020-11-27
EP3527263A1 (en)	2019-08-21
CY1121763T1 (el)	2020-07-31
PT2997023T (pt)	2017-05-31
EP3231801B1 (en)	2019-02-13
IL264409A (en)	2019-02-28
US10435392B2 (en)	2019-10-08
JP2021008493A (ja)	2021-01-28
US20160289215A1 (en)	2016-10-06
IL282644A (en)	2021-06-30
US20230159501A1 (en)	2023-05-25
AU2014265279B2 (en)	2018-09-27
PH12015502563B1 (en)	2019-04-26
IL264409B (en)	2021-05-31
TWI719401B (zh)	2021-02-21
EP2997023A1 (en)	2016-03-23
IL287313A (en)	2021-12-01
US20250206726A1 (en)	2025-06-26
US9382231B2 (en)	2016-07-05
CA2911536C (en)	2021-07-20
AU2021202685B2 (en)	2022-11-17
TW202116320A (zh)	2021-05-01
SMT202100040T1 (it)	2021-03-15
SMT201900223T1 (it)	2019-07-11
NZ753636A (en)	2020-11-27
RS64591B1 (sr)	2023-10-31

Publication	Publication Date	Title
DK4275756T3 (da)	2025-09-29	Bipyrazol-derivater som jak-hæmmere
DK3071203T3 (da)	2021-03-15	Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer
LT3057586T (lt)	2020-03-10	Bromodomeno inhibitoriai
EP2969007A4 (en)	2016-07-27	HISTONE DEMETHYLASE INHIBITORS
HUE049794T2 (hu)	2020-10-28	Új aminopirimidin származékok
DK3019496T3 (da)	2019-12-09	Pyrimidinderivater som kinaseinhibitorer
AR095266A1 (es)	2015-09-30	Inhibidores de bromodominios tetraciclicos
DK2981526T3 (da)	2022-02-07	Naphthylureaderivater til anvendelse som kinaseinhibitorer
PT2964616T (pt)	2017-08-08	Inibidores da neprilisina
DK2952513T3 (da)	2019-09-02	Azolbenzenderivat
PL2945641T3 (pl)	2020-06-15	Cykloalkinowe pochodne sacharydów
DK3319970T3 (da)	2019-12-02	Pyrido-oxazinonderivater som tnap-hæmmere
DK3007725T3 (da)	2019-10-21	Beta-glycolipider til anvendelse som adjuvanser
DK3027594T3 (da)	2022-11-14	2-benzoylaminobenzamidderivater som bcl-3-hæmmere
DK3484875T3 (da)	2021-06-28	Pyrazolylaminobenzimidazolderivater som JAK-hæmmere
EP3009444A4 (en)	2016-11-30	ALPHA-oxoacyl-Amino-caprolactam derivative
ITMI20130606A1 (it)	2014-10-13	Composti naftoeterodiazolici disostituiti
TH1501003353A (th)	2016-12-21	สารประกอบชนิดใหม่
TH1501002690A (th)	2016-11-07	สารประกอบใหม่
TH1401007086A (th)	2016-05-19	อนุพันธ์อัลริลเอทธินิล
UA26298S (uk)	2014-01-27	Сірник
UA26413S (uk)	2014-02-10	Сірник